Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/BRVE/vs peers

BRVEBraveheart Bio, Inc.vs its industry peers

A metric-by-metric comparison of Braveheart Bio, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.

Full peer comparison
Peers: same SEC industry
CompanyMarket capP/E (TTM)P/BP/SRevenue growth (YoY)Earnings growth (YoY)EBIT marginROEROICPiotroski F1y total returnDividend yield
BRVEBraveheart Bio, Inc.This$1.9B#8———————————
PVLAPALVELLA THERAPEUTICS, INC.$2.2B#1—10.2x#951.6x#865.3%#4-139.3%#8-90.2%#6-19.2%#5——99.0%#2—
PRGOPERRIGO Co plc$2.2B#2—0.9x#10.5x#1-2.8%#10-729.7%#12-26.4%#3-56.7%#9-20.9%#34#1-18.0%#67.3%#1
HRMYHarmony Biosciences Holdings, Inc.$2.2B#312.0x#12.2x#42.5x#321.5%#89.1%#624.0%#115.9%#125.5%#14#126.2%#5—
ZYMEZymeworks Inc.$2.1B#4—26.6x#1120.2x#538.9%#733.9%#2-87.3%#5-100.9%#10——59.5%#3—
SEPNSepterna, Inc.$2.0B#5—5.3x#644.4x#74174.5%#131.9%#3-148.6%#7-12.6%#3——118.1%#1—
TRVITrevi Therapeutics, Inc.$2.0B#6—6.1x#7——10.7%#5—-13.3%#4——29.6%#4—
SRPTSarepta Therapeutics, Inc.$2.0B#7—1.3x#21.1x#24.3%#9-403.3%#11-37.5%#4-46.7%#8-73.0%#4—-24.2%#7—
XERSXeris Biopharma Holdings, Inc.$1.9B#9——6.5x#443.7%#6101.0%#18.5%#2—20.6%#2———
PGENPRECIGEN, INC.$1.9B#10—43.1x#12194.1x#10146.7%#2-98.6%#7-1141.1%#9-575.1%#12-91.2%#5———
AGIOAGIOS PHARMACEUTICALS, INC.$1.9B#11—1.8x#334.5x#648.0%#5-161.3%#10-873.9%#8-40.3%#7————
ZBIOZenas BioPharma, Inc.$1.8B#12—7.5x#8184.9x#9100.0%#3-140.6%#9-3830.6%#10-152.9%#11-296.6%#6———
SLS$1.8B#13—13.0x#10—-100.0%#1113.0%#4—-19.5%#6————
GENB$1.8B#14—3.9x#5————0.0%#2————

Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-04.

Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice

BRVE's peers

PVLAPRGOHRMYZYMESEPNTRVISRPTXERSPGENAGIOZBIOSLSGENB
← BRVE overview